The following antibodies were obtained from the indicated suppliers: rabbit anti-IDH1 (Cell Signaling Technology, Cat#8137S, 1:1000), rabbit anti-TMLHE (Proteintech, Cat#16621-1-AP, 1:1000), rabbit anti-Cyclin E (Cell Signaling Technology, Cat#4129S, 1:1000), mouse anti-Vinculin (Sigma-Aldrich, Cat#V9131, 1:1000), rabbit pan-acetyl H3 (Active Motif, Cat#61638, 1:1000), rabbit Total Histone H3 (Millipore, Cat#05-928, 1:1000), rabbit pan-acetyl H4 (Active Motif, Cat#39925, 1:1000), rabbit Total Histone H4 (Cell Signaling Technology, Cat#13919S, 1:1000), rabbit H4K8ac (GeneTex, Cat#GTX128957, 1:1000), rabbit H4K12ac (Cell Signaling Technology, Cat#13944S, 1:1000), rabbit H4K23ac (Active Motif, Cat#39131, 1:1000), mouse anti-Beta Actin (Sigma-Aldrich, Cat#A1978, 1:1000), rat anti-BrdU (Abcam, Cat#ab6326, 1:500), mouse anti-phospho-Histone H2A.X (Ser139, 1:500) (Millipore Sigma, Cat#05-636), rabbit anti-53BP1 (Bethyl, Cat # A300-272A, 1:500), mouse BRCA1 (Santa Cruz biotechnology, Cat#sc-6954, 1:500)

Anyone with chronic kidney disease, a history of kidney stones, or reduced kidney function should have their renal function assessed and discuss suitability with their GP or renal specialist before starting, just as they would for the injection
patients switched to placebo regained about 6.9% (JAMA 2021)
Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (6.1), Clinical Studies (14.4)]